SAR 425899
Alternative Names: SAR-425899Latest Information Update: 05 Nov 2023
At a glance
- Originator Sanofi
- Class Antihyperglycaemics; Obesity therapies
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 08 Apr 2019 Sanofi terminates the phase II Restore trial in Non-alcoholic fatty liver disease prior to patient enrolment due to Sponsor's decision to cancel TRIAL, not related to safety concern (NCT03437720)
- 31 Dec 2018 Discontinued - Phase-I for Obesity in USA, Sweden, Germany (SC)
- 31 Dec 2018 Discontinued - Phase-I for Type 2 diabetes mellitus in France, Sweden (SC)